Invité Ven 7 Mai 2010 - 12:50Encore un article ds une super revue. Ne l'ayant pas encore lu, je ne peux vs en faire un résumé, ms je l'ai et ceux qui veulent y accéder peuvent me le demander, juste donnez-moi un mail perso q je puisse l'attacher
Nat Rev Neurol. 2010 May;6(5):247-55. Epub 2010 Apr 20.
Stem cell transplantation in multiple sclerosis: current status and future prospects.
Martino G, Franklin RJ, Van Evercooren AB, Kerr DA; Stem Cells in Multiple Sclerosis (STEMS) Consensus Group.
Institute of Experimental Neurology-DIBIT 2, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy. martino.gianvito@hsr.it
Abstract
This article provides an overview of the current knowledge relating to the potential use of transplanted stem cells in the treatment of patients with multiple sclerosis (MS). Two types of stem cells, CNS-derived neural stem/precursor cells (NPCs) and bone marrow-derived mesenchymal stem cells (MSCs) are considered to provide reproducible and robust therapeutic effects when intravenously or intrathecally injected into both rodents and primates with experimental autoimmune encephalomyelitis. Furthermore, preliminary safety data concerning the use of intrathecally injected autologous MSCs in patients with progressive MS are available. We discuss how the data gathered to date challenge the narrow view that the therapeutic effects of NPCs and MSCs observed in the treatment of MS are accomplished solely by cell replacement. Both types of stem cell, when transplanted systemically, might instead influence disease outcome by releasing a plethora of factors that are immunomodulatory or neuroprotective, thereby directly or indirectly influencing the regenerative properties of intrinsic CNS stem/precursor cells.
Nat Rev Neurol. 2010 May;6(5):247-55. Epub 2010 Apr 20.
Stem cell transplantation in multiple sclerosis: current status and future prospects.
Martino G, Franklin RJ, Van Evercooren AB, Kerr DA; Stem Cells in Multiple Sclerosis (STEMS) Consensus Group.
Institute of Experimental Neurology-DIBIT 2, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy. martino.gianvito@hsr.it
Abstract
This article provides an overview of the current knowledge relating to the potential use of transplanted stem cells in the treatment of patients with multiple sclerosis (MS). Two types of stem cells, CNS-derived neural stem/precursor cells (NPCs) and bone marrow-derived mesenchymal stem cells (MSCs) are considered to provide reproducible and robust therapeutic effects when intravenously or intrathecally injected into both rodents and primates with experimental autoimmune encephalomyelitis. Furthermore, preliminary safety data concerning the use of intrathecally injected autologous MSCs in patients with progressive MS are available. We discuss how the data gathered to date challenge the narrow view that the therapeutic effects of NPCs and MSCs observed in the treatment of MS are accomplished solely by cell replacement. Both types of stem cell, when transplanted systemically, might instead influence disease outcome by releasing a plethora of factors that are immunomodulatory or neuroprotective, thereby directly or indirectly influencing the regenerative properties of intrinsic CNS stem/precursor cells.
